How to buy Blueprint Medicines Corporation stock

Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 429 staff and has a trailing 12-month revenue of around 0.00.

Blueprint Medicines Corporation share price

Use our graph to track the performance of BPMC stocks over time.

Blueprint Medicines Corporation shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$56.00 - $125.61
50-day moving average	$97.81
200-day moving average	$102.00
Wall St. target price	$116.31
PE ratio	17.3703
Dividend yield	N/A (0%)
Earnings per share (TTM)	$5.59

Buy Blueprint Medicines Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Blueprint Medicines Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Blueprint Medicines Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Blueprint Medicines Corporation under- or over-valued?

Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Blueprint Medicines Corporation's P/E ratio

Blueprint Medicines Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Blueprint Medicines Corporation shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Blueprint Medicines Corporation's EBITDA

Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $315.3 million.

The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.

Blueprint Medicines Corporation financials

Revenue TTM	$793.7 million
Operating margin TTM	38.89%
Gross profit TTM	$466.5 million
Return on assets TTM	15.91%
Return on equity TTM	32.45%
Profit margin	39.55%
Book value	$25.44
Market capitalisation	$5.7 billion

TTM: trailing 12 months

Shorting Blueprint Medicines Corporation shares

There are currently 3.3 million Blueprint Medicines Corporation shares held short by investors – that's known as Blueprint Medicines Corporation's "short interest". This figure is 4.2% up from 3.1 million last month.

There are a few different ways that this level of interest in shorting Blueprint Medicines Corporation shares can be evaluated.

Blueprint Medicines Corporation's "short interest ratio" (SIR)

Blueprint Medicines Corporation's "short interest ratio" (SIR) is the quantity of Blueprint Medicines Corporation shares currently shorted divided by the average quantity of Blueprint Medicines Corporation shares traded daily (recently around 383155.63380282). Blueprint Medicines Corporation's SIR currently stands at 8.52. In other words for every 100,000 Blueprint Medicines Corporation shares traded daily on the market, roughly 8520 shares are currently held short.

However Blueprint Medicines Corporation's short interest can also be evaluated against the total number of Blueprint Medicines Corporation shares, or, against the total number of tradable Blueprint Medicines Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Blueprint Medicines Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Blueprint Medicines Corporation shares in existence, roughly 60 shares are currently held short) or 0.0564% of the tradable shares (for every 100,000 tradable Blueprint Medicines Corporation shares, roughly 56 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Blueprint Medicines Corporation.

Find out more about how you can short Blueprint Medicines Corporation stock.

Blueprint Medicines Corporation share dividends

We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.

Blueprint Medicines Corporation share price volatility

Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $56 up to $125.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.7314. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).

Blueprint Medicines Corporation overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.

Frequently asked questions

• What percentage of Blueprint Medicines Corporation is owned by insiders or institutions?

  Currently 0.818% of Blueprint Medicines Corporation shares are held by insiders and 100.805% by institutions.

• How many people work for Blueprint Medicines Corporation?

  Latest data suggests 429 work at Blueprint Medicines Corporation.

• When does the fiscal year end for Blueprint Medicines Corporation?

  Blueprint Medicines Corporation's fiscal year ends in December.

• Where is Blueprint Medicines Corporation based?

  Blueprint Medicines Corporation's address is: 45 Sidney Street, Cambridge, MA, United States, 02139-4133

• What is Blueprint Medicines Corporation's ISIN number?

  Blueprint Medicines Corporation's international securities identification number is: US09627Y1091

• What is Blueprint Medicines Corporation's CUSIP number?

  Blueprint Medicines Corporation's Committee on Uniform Securities Identification Procedures number is: 09627Y109